Skip to main content Accesibility Help
×
×
Home

Beware of Surrogate Outcome Measures

  • Peter C. Gøtzsche (a1), Alessandro Liberati (a2), Valter Torri (a2) and Luca Rossetti (a3)
Abstract

Surrogate outcome measures may speed up clinical research if they can be measured earlier in a study than the primary outcome of interest. We review the justification for their use and conclude that reliance on them may be harmful. Results obtained with surrogates should therefore be regarded as preliminary. Large, definitive trials with clinically relevant outcomes should always be performed before new interventions are accepted.

Copyright
References
Hide All
1.Aboulker, J. P., & Swart, A. M., Concorde Coordinating Committee. Preliminary analysis of the Concorde trial. Lancet, 1993, 341, 890–91.
2.Antman, E. M., Lau, J., Kupelnick, B., et al. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts: Treatments for myocardial infarction. Journal of the American Medical Association, 1992, 268, 240–48.
3.Bentzon, M. W., Gad, I., & Halberg, P.Influence of previous gold treatment and other patient variables on outcome of treatment with disease modifying anti-rheumatic drugs (DMARD) in patients with rheumatoid arthritis. Clinical Rheumatology, 1986, 5, 3948.
4.Boissel, J-P., Collett, J-P., Moleur, P., & Haugh, M.Surrogate endpoints: A basis for a rational approach. European Journal of Clinical Pharmacology, 1992, 43, 235–44.
5.The CAST investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New England Journal of Medicine, 1989, 321, 406–12.
6.Chalmers, T. C., Frank, C. S., & Reitman, D.Minimizing the three stages of publication bias. Journal of the American Medical Association, 1990, 263, 1392–95.
7.The Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. New England Journal of Medicine, 1980, 303, 1038–41.
8.The Diabetes Control and Complication Trials Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine, 1993, 329, 977–86.
9.Gruppo Italiano per lo Studiodella Soprawivenza nell’Infarto Miocardico. GISSI-3:effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet, 1994, 343, 1115–22.
10.Harris, S. T., Watts, N. B., Jackson, R. D., et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. American Journal of Medicine, 1993, 95, 557–67.
11.Hillis, A.Surrogate end-points in clinical trials: Ophthalmologic disorders. Statistics in Medicine, 1989, 8, 427–30.
12.Impact Research Group. International mexiletine and placebo antiarrhythmic coronary trial, I: Report on arrhythmia and other findings. Journal of the American College of Cardiology, 1984, 4, 1148–63.
13.Lewis, E. J., Hunsicker, L. G., Lan, S-P., et al. for the Lupus Nephritis Collaborative Study Group. A controlled trial of plasmapheresis therapy in severe lupus nephritis. New England Journal of Medicine, 1992, 326, 1373–79.
14.Miller, F. W., Leitman, S. F., Cronin, M. E., et al. Controlled trial of plasma exchange and leuka-pheresis in polymyositis and dermatomyositis. New England Journal of Medicine, 1992, 326, 1380–84.
15.Mullen, M., Mullen, B., & Carey, M.The association between beta-agonist use and death from asthma: A meta-analytic integration of case-control studies. Journal of the American Medical Association, 1993, 270, 1842–45.
16.Riggs, B. L., Hodgson, S. F., O’Fallon, W. M., et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. New England Journal of Medicine, 1990, 322, 802–09.
17.Rossetti, L., Marchetti, I., Orzalesi, N., et al. Randomized clinical trials on medical treatment of glaucoma: Are they appropriate to guide clinical practice? Archives of Ophthalmology, 1993, 111, 96103.
18.Smith, G. D., Song, F., & Sheldon, T. A.Cholesterol lowering and mortality: The importance of considering the initial level of risk. British Medical Journal, 1993, 306, 1367–73.
19.Sommer, A., Tielsch, J., Katz, J., et al. Relationship between intraocular pressure and primary open-angle glaucoma among white and black Americans: The Baltimore Eye Survey. Archives of Ophthalmology, 1991, 109, 1090–95.
20.Sponsel, W. E.Tonometry in question: Can visual screening play a more decisive role in glaucoma diagnosis and management? Survey of Ophthalmology, 1989, 33(suppl.), 291300.
21.Tiné, F., Liberati, A., Craxi, V., et al. Interferon treatment in patients with chronic hepatitis B: A meta-analysis of the published literature. Journal of Hepatology, 1993, 18, 154–62.
22.Torri, V., Simon, R., Russek-Cohen, E., et al. Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy.Journal of the National Cancer Institute, 1992, 84, 407–14.
23.Ward, J.Prevention of invasive Haemophilus influenzae type b disease: Lessons from vaccine efficacy trials. Vaccine, 1991, 9, S17–S24.
24.Wulff, H., Pedersen, S. A., & Rosenberg, R.Philosophy of medicine. Oxford: Blackwell, 1986.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed